An Eli Lilly spokesperson said: "We expect Zepbound to be used as part of an ongoing disease management strategy for adults with obesity, in addition to a reduced-calorie diet and increased physical activity." The FDA told Fortune that it regulates the marketing and distribution of prescription drugs, and that companies are responsible for not misleading customers and being truthful in their product marketing, but the agency declined to comment on any specific companies and whether it had investigated or issued any warnings, noting that the FDA "generally does not comment on pending or potential compliance matters." 'We wanted to make sure that we stayed on message' Calibrate was one of the first weight-loss companies to enter what has become a saturated space
Always follow the specific storage instructions on the IMP label or trial protocol
Recent studies published in 2024 show an increased risk of NAION, particularly in patients using these drugs for weight loss
Educational status at index date was obtained from the Populations education register using the International Standard Classification of Education (ISCED): 0-2 (basic education) 3 + 5 (middle education) and 6-8 (high education) [25]
However, most of these studies were done with liraglutide or other daily GLP-1RA, which are not as effective for weight loss as the newer GLP-1RA (e.g., semaglutide or tirzepatide)
